DNARx
DNARx is dedicated to transforming gene therapy through innovative, nonviral DNA-based platforms like HEDGES, aiming to provide safe, effective, and versatile treatments for a wide range of diseases including cancer, genetic disorders, and pandemic infections. Their mission is to develop the safest and most effective gene delivery tools to improve patient outcomes worldwide.
Industries
Nr. of Employees
small (1-50)
DNARx
San Francisco, California, United States, North America
Products
Nonviral DNA-based gene delivery platform
A platform combining DNA constructs and liposome-based carriers designed for systemic delivery, tunable-duration expression, multigene and large-construct expression, and repeat dosing in preclinical models.
Nonviral DNA-based gene delivery platform
A platform combining DNA constructs and liposome-based carriers designed for systemic delivery, tunable-duration expression, multigene and large-construct expression, and repeat dosing in preclinical models.
Services
Preclinical gene therapy development and testing
Design and execution of preclinical programs including DNA vector design, formulation development, systemic and localized delivery, animal efficacy studies, and bioanalytical assessment of expressed products.
Nonviral DNA vector formulation and manufacturing development
Formulation optimization and manufacturing approaches for nonviral DNA-encoded therapeutics with an emphasis on scalable, lower-complexity production compared with viral vectors.
Partnerships for pandemic countermeasures and biodefense
Program development and execution in collaboration with government sponsors to generate DNA-encoded prophylactics and therapeutics for pandemic pathogens.
Preclinical gene therapy development and testing
Design and execution of preclinical programs including DNA vector design, formulation development, systemic and localized delivery, animal efficacy studies, and bioanalytical assessment of expressed products.
Nonviral DNA vector formulation and manufacturing development
Formulation optimization and manufacturing approaches for nonviral DNA-encoded therapeutics with an emphasis on scalable, lower-complexity production compared with viral vectors.
Partnerships for pandemic countermeasures and biodefense
Program development and execution in collaboration with government sponsors to generate DNA-encoded prophylactics and therapeutics for pandemic pathogens.
Expertise Areas
- Nonviral gene delivery
- Multigene and large-construct expression
- Formulation-driven expression control
- Preclinical in vivo development and efficacy testing
Key Technologies
- Nonviral DNA delivery
- Liposome-based carrier systems
- Enhancer-promoter vector design
- Large-capacity DNA construct engineering